Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival

Chlebowski, Rowan T.; Aragaki, Aaron K.; Anderson, Garnet L.; Simon, Michael S.; Manson, JoAnn E.; Neuhouser, Marian L.; Pan, Kathy; Stefanic, Marcia L.; Rohan, Thomas E.; Lane, Dorothy S.; Qi, Lihong; Snetselaar, Linda; Prentice, Ross L.

doi:10.1001/jamaoncol.2018.1212

Cited by 63 publications

(37 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple epidemiological studies indicate that nutritional status has a major impact on BC incidence 17 , and it is now established that dietary interventions can mediate therapeutically relevant immunostimulatory effects 18 . We therefore analyzed the impact of nutritional interventions on M/D-driven carcinogenesis in WT C57BL/6 mice.…”

Section: Resultsmentioning

confidence: 99%

“…M/D-driven tumors emerge in immunocompetent hosts via an ER-dependent oncogenic process, and progress as they evade immunosurveillance, culminating with the establishment of mammary tumors with a luminal B (highly proliferative HER2 − ER + VIM − ) phenotype that fails to convert into basal (ER − VIM + ) over time or upon treatment. Moreover, M/D-driven tumors developing in immunocompetent mice resemble human luminal B BCs as they exhibit common PI3KCA mutations 32 , poor immune infiltration coupled to limited sensitivity to ICBs 8 , and can be accelerated by nutritional interventions that have been epidemiologically linked to increased propensity for HR + BC in humans, such as a HFD 17 . One of the caveats of this model relates to the fact that while ER + BC is the most common form of BC in women, only a fraction of cases of ER + BC is linked to the use of progestins 11 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

et al. 2020

View full text Add to dashboard Cite

Hormone receptor (HR)+ breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR+ BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts. We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2− BC, including limited immune infiltration and poor sensitivity to ICBs. M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance. Safe nutritional measures including nicotinamide (NAM) supplementation efficiently delay M/D-driven oncogenesis by reactivating immunosurveillance. NAM also mediates immunotherapeutic effects against established M/D-driven and transplantable BC, largely reflecting increased type I interferon secretion by malignant cells and direct stimulation of immune effector cells. Our findings identify NAM as a potential strategy for the prevention and treatment of HR+ BC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The most commonly used supplements were found to be fish oil, multivitamins and minerals and evening primrose oil. 16 In our study, taken food supplements did not increase significantly after the diagnosis compared to the control group (p>0.05). Taken food supplements are identified as n 3 , vitamin D, green tea and ginger.…”

Section: Discussioncontrasting

confidence: 46%

Evaluation of the eating habits of breast cancer patients

et al. 2020

View full text Add to dashboard Cite

Objective: To determine the relationship between the dietary characteristics of breast cancer patients. Methods: Patients with breast cancer whose treatments have finished and are in remission formed the study group and healthy people formed the control group. Demographic, anthropometric characteristics, food consumption frequency form and exercise status were recorded with all groups. Data analysis was done by SPSS 22. Results: In the study group, mean carbohydrate percentage was lower, while fat, fat percentage, monosaccharide, glucose, fructose, omega3(n3), saturated fatty acids(SFA), monounsaturated fatty acids (MUFA), vitamin A, C, E, B6, biotin and copper values were significantly higher (p<0.05). Recurrence was observed in seven patients (7.1%) during the follow-up period, hormone receptor levels (ER) and vitamin B2 intake (accuracy 93.9%) were inversely related to the recurrence of the disease (p=0.02). Conclusions: While the percentage of carbohydrate taken was lower in study group; total fat, n3, SFA, MUFA, monosaccharide, glucose, fructose, water-soluble fiber, B6, biotin and copper values were higher. Further studies are needed for vitamin B2 deficiency in patients with recurrence. doi: https://doi.org/10.12669/pjms.36.7.2368 How to cite this:Tapan TK, Iyigun ZE, Ilgun S, Ozmen V. Evaluation of the eating habits of breast cancer patients. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2368 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…FASN inhibitor TVB2640, alone or in combination, is currently being tested in different clinical trials (ClinicalTrials.gov identifiers: NCT02223247, NCT03032484, NCT02980029, and NCT03179904), and preliminarily shows anti-tumour activity 53 . Although low fat diets on their own seem to have minor effects on human cancer progression 54 , our results suggest that decreasing lipid availability or inhibiting lipid uptake should be considered as an adjuvant for therapies that target de novo lipogenesis. Although the inhibition of lipid transporters could be one option 55 , the presence of several uptake mechanisms could become a major obstacle in some tumour types, hence low-fat diets represent an attractive alternative.…”

Section: Discussionmentioning

confidence: 78%

Identifying strategies to target the metabolic flexibility of tumours

Méndez-Lucas

Lin

Driscoll

et al. 2020

Preprint

View full text Add to dashboard Cite

SummaryPlasticity of cancer metabolism can be a major obstacle for efficient targeting of tumour-specific metabolic vulnerabilities. Here, we identify and quantify the compensatory mechanisms following the inhibition of major pathways of central carbon metabolism in c-MYC-induced liver tumours. We find that glutaminase isoform Gls2, expressed in normal liver, compensates for the deletion of Gls1 isoform expressed in tumours. Inhibiting both glutaminases significantly delays tumourigenesis but does not completely block glutamine catabolism through the Krebs cycle. We reveal that glutamine catabolism is then driven by amidotransferases. Consistently, the synergistic effect of glutaminase and amidotransferase inhibitors on proliferation of mouse and human tumour cells is observed in vitro and in vivo. Furthermore, when Gls1 is deleted the Krebs cycle activity and tumour formation can also be significantly affected if glycolysis is co-inhibited (Gls1KO/Hk2KO). Finally, the inhibition of either serine (Psat1KO) or fatty acid (FasnKO) biosynthesis can be compensated by uptake of circulating nutrients. Thus, removing these nutrients from the diet produces synergistic effects on suppression of tumourigenesis. These results highlight the high flexibility of tumour metabolism and demonstrate how targeting compensatory mechanisms can improve a therapeutic outcome.

show abstract

Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival

Abstract: ClinicalTrials.gov Identifier: NCT00000611.

Cited by 63 publications

References 40 publications

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Evaluation of the eating habits of breast cancer patients

Identifying strategies to target the metabolic flexibility of tumours

Contact Info

Product

Resources

About